Pepscan

About:

Pepscan employs protein mimicry techniques for the R&D of therapeutic drugs and a range of specialty peptide products and services.

Website: http://www.pepscan.com/

Top Investors: PPM Oost NV, Lupus Ventures, MKB & Technofonds Flevoland, Biox Biosciences, Technofund Flevoland

Description:

Pepscan is an all-in-one partner in peptides, building on 25 years of experience in advancing and applying peptide expertise to facilitate clients in the development and production of peptides. At its end-to-end facility in Lelystad, the Netherlands, Pepscan offers a range of patented technologies, phage display capabilities, a lead-optimization array platform, and production facilities for R&D- to GMP-grade peptides, including libraries and neoantigen vaccines. Among its patents is the CLIPS technology, which locks peptides into active conformations. With its epitope mapping service platform, Pepscan also supports biotech companies in developing their antibody pipelines. The underlying protein mimicry platform delivers binding insights, even in cases where other technologies, such as linear, fall short.

Total Funding Amount:

12M EUR

Headquarters Location:

Lelystad, Flevoland, The Netherlands

Founded Date:

1999-01-01

Contact Email:

info(AT)pepscan.com

Founders:

Rob Meloen

Number of Employees:

11-50

Last Funding Date:

2006-09-19

IPO Status:

Private

Industries:

© 2025 bioDAO.ai